Volume 22, Issue 2 (6-2019)
J Arak Uni Med Sci 2019, 22(2): 1-10 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Omidi F, Nokani M, Alaghmand A. Evaluation of the Efficacy of Memantine in Combination with Ritalin on the Severity of Hyperactivity and Attention Deficit Symptoms in Children. J Arak Uni Med Sci 2019; 22 (2) :1-10
URL: http://jams.arakmu.ac.ir/article-1-5649-en.html
URL: http://jams.arakmu.ac.ir/article-1-5649-en.html
1- Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran. , dromidi.ac@gmail.com
2- Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran.
2- Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran.
Abstract: (9020 Views)
Background and Aim: Attention Deficit Hyperactivity Disorder is a common psychiatric disorder in children and paying attention to drugs that were used in this disorders are important. This study compares the efficacy of Ritalin with Memantin that is added to Ritalin on the severity of ADHD and attention deficit disorder in children.
Materials and Methods: This study is a clinical trial. All of 76 patients with diagnostic criteria for ADHD had been selected from the group of children that they were 7-12 years old, through diagnostic interviews in control & experimental groups based on DSM-V. At first, both groups filled out the Connors parent questionnaire for assessing the severity of the symptoms. Then, Ritalin was prescribed for the patients in the control group and Memantin was added to Ritalin for the patients in the experimental group for one month. The two groups again completed the questionnaire and the effectiveness of drugs was compared.
Ethical Considerations: This study with research ethics code 139510 has been approved by research ethics committee at Arak university of medical sceinces and also has been registered with code IRCT2016080829268N1 at Iranian Registry of Clinical Trials (IRCT).
Findings: According to the P-value of this test, there was no significant difference between the two groups after taking the drugs, which is equal to 0.324 and more than 0.05. But in that groups, there was a significant difference in severity of the symptoms between groups before and after taking the drugs.
Conclusion: Although the symptoms severity of hyperactivity decreased, there was no significant difference between these two groups. The Memantin added to Ritalin did not have a special effect on reducing the severity of symptoms compared to Ritalin. We can conclude the Ritalin might have had a significant effect on the symptoms reduction.
Materials and Methods: This study is a clinical trial. All of 76 patients with diagnostic criteria for ADHD had been selected from the group of children that they were 7-12 years old, through diagnostic interviews in control & experimental groups based on DSM-V. At first, both groups filled out the Connors parent questionnaire for assessing the severity of the symptoms. Then, Ritalin was prescribed for the patients in the control group and Memantin was added to Ritalin for the patients in the experimental group for one month. The two groups again completed the questionnaire and the effectiveness of drugs was compared.
Ethical Considerations: This study with research ethics code 139510 has been approved by research ethics committee at Arak university of medical sceinces and also has been registered with code IRCT2016080829268N1 at Iranian Registry of Clinical Trials (IRCT).
Findings: According to the P-value of this test, there was no significant difference between the two groups after taking the drugs, which is equal to 0.324 and more than 0.05. But in that groups, there was a significant difference in severity of the symptoms between groups before and after taking the drugs.
Conclusion: Although the symptoms severity of hyperactivity decreased, there was no significant difference between these two groups. The Memantin added to Ritalin did not have a special effect on reducing the severity of symptoms compared to Ritalin. We can conclude the Ritalin might have had a significant effect on the symptoms reduction.
References
1. Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K,Faraone SV. Advances in understanding and treating ADHD.BMC Medicine. 2011; 9:7
2. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders DSM IV-TR, 4th edn (Text Revision). American Psychiatric Press: Washington DC. 2000.
3. Kaplan HI, Sadock BJ Ed. Synopsis of psychiatry: Behavioral sciences/clinical psychiatry 9th Eds. Philadelphia: Lippincott Williams & Wilkins. 2015.
4. Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J. A pilot open label prospective study of memantin monotherapy in adults with ADHD. World J Biol Psychiatry. 2013; (4):291-8.
5. Sedighi N. Self-instructional efficacy in the improvement of ADHD-attention deficit hyperactivity disorder in children with ADHD. Master's Thesis. Islamic Azad University, Science and Research Branch of Arak. [MSc thesis]. Islamic Azad University, Science and Research Branch of Arak. 2013.
6. Smith, Quack G: Cerebrospinal fluid and serum concentrations of the N-Methyl-Aspartate (NMDA) receptor antagonist memantin in man. Neurosci Letts. 1996; 195:137–139.
7. Nokani M. Computer-aided cognitive rehabilitation in children with hyperactivity disorder - attention deficit. [PHD thesis]. Shahid beheshti university. 2010.
8. Greenhill LL, Hechtman LI. Attention-Deficit/Hyperactivity Disorder. In: Sadock BJ, Sadock VA, Ruiz P. Comprehensive Text Book of Psychiatry. 9th ed. Philadelphia: Lippincott, Williams & Wilkins. 2009; 3560-72.
9. Russell, Langley K, Mills’ S, Stephens M, Lawson D, Gavan C, et al. Follow-up of genetic linkage findings on chromosome 16p13: Evidence of association of Nmethyl-Daspartate glutamate receptor 2A gene polymorphism with ADHD. Moll Psychiatry. 2001; 9:169–173.
10. Findling RL, McNamara NK, Stansbrey RJ, Maxhimer R, Periclou A, Mann A, Graham SM. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol. 2007; 17(1):19-33.
11. Erikson C., Posey D., Stigler k., Mullet J., Katschke A., Mcdougle C. Aretrospective study of memantine in children and adolescent with pervasive developmental disorders. Psychopharmocology. 2007; 191 (1), 141-147.
12. Mohammadi MR, Mohammadzadeh S, Akhondzadeh S,. PhMemantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial. Iran J Psychiatry. 2015; 10(2): 106-114.
13. Biederman J, Fried R, Tarko L, Surman C, Spencer T, Pope A, Grossman R, McDermott K, Woodworth KY, Faraone S. Memantine in the Treatment of Executive Function Deficits in Adults with ADHD: A Pilot-Randomized Double-Blind Controlled Clinical Trial. Journal of Attention Disorders (Impact Factor: 2.4). 06/2014; DOI: 10.1177/1087054714538656.
14. Hosenbocus S, Chahal R. Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2013; 22(2): 166–171.
15. Weiss M, Weiss G. Attention Deficit- Hyperactivity Disorder. In: Martin A, Volkmar FR. Lewis's Child and Adolescent Psychiatry: A Comprehensive Textbook. 3rd ed. Philadelphia (PA): Lippincott, Williams & Wilkins. 2002; 645-51.
16. Brock SE, Clinton A. Diagnosis of attention deficit/ hyperactivity disorder (AD/HD) in childhood: A review of the literature. J child Dev. 2007; (12):73-91.
17. Shhayyan A, Shahim TV, Beaming Laya, Yousefi Farida. Normalization, Factor analysis and reliability of the short form of special Conners Parent Ratin Scale for children 6 to 11 years Shiraz city. Journal of Psychological Studies. 2007; 3(3): 97-120.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
